Insights from Pharmaceutical Biotechnology into Phenolic Biopharmaceuticals against COVID-19 / Nidia Cabral-Hipólito, Brenda Molina-Ramírez, María-de-la-Luz Sevilla-González, Rocío Meza-Velázquez, Rubén García-Garza, Sergio-Everardo Velázquez Gauna, Irais Castillo-Maldonado, Dealmy Delgadillo-Guzmán, Mario-Alberto Rivera-Guillén, Luis-Benjamín Serrano-Gallardo, María-del-Carmen Vega-Menchaca, Agustina Ramírez-Moreno, David Pedroza-Escobar
Background: The COVID-19 pandemic had infected more than 3.5M people around the world and more than 250K people died in 187 countries by May 2020. The causal agent of this disease is a coronavirus whose onset of symptoms to death range from 6 to 41 days with a median of 14 days. This period is dependent on several factors such as the presence of comorbidities, age and the efficiency of the innate or adaptive immune responses. Methods: The effector mechanisms of both types of immune responses depend on the pathogen involved. In the case of a viral infection, the innate immune response may approach the harmful virus through pattern recognition receptors inducing an antiviral state. Results: On the other hand, the adaptive immune response activates antibody production to neutralize or eliminate the virus. Phenolics are plant secondary metabolites with many biological activities for plants and humans against infection. Chemical modification of proteins may enhance their biological properties; thus, a protein of medical interest, for instance, a viral protein can be used as a scaffold to build a biopharmaceutical conjugated or complexated with phenolics exhibiting structural complexity or biological activities to achieve effective phenolic-protein-based therapeutics like vaccine adjuvant complexes, immunogen conjugates, and antiviral conjugates. Conclusion: Pharmaceutical biotechnology applies the principles of biotechnology to develop biopharmaceuticals for protein-based therapeutics; such as adjuvants, recombinant proteins, monoclonal antibodies, and antivirals. As neither a vaccine nor a treatment for COVID-19 is currently available, this manuscript focuses on insights from pharmaceutical biotechnology into phenolic biopharmaceuticals against COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 22(2021), 14, Seite 1848- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cabral-Hipólito, Nidia [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (9 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL008975043 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL008975043 | ||
| 003 | DE-627 | ||
| 005 | 20231128151001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220316s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL008975043 | ||
| 035 | |a (KFL)prod_DARH_.CD8B337EBA86BD3D02C54E0A3F6D9D8DD05E982E | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Cabral-Hipólito, Nidia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insights from Pharmaceutical Biotechnology into Phenolic Biopharmaceuticals against COVID-19 |c Nidia Cabral-Hipólito, Brenda Molina-Ramírez, María-de-la-Luz Sevilla-González, Rocío Meza-Velázquez, Rubén García-Garza, Sergio-Everardo Velázquez Gauna, Irais Castillo-Maldonado, Dealmy Delgadillo-Guzmán, Mario-Alberto Rivera-Guillén, Luis-Benjamín Serrano-Gallardo, María-del-Carmen Vega-Menchaca, Agustina Ramírez-Moreno, David Pedroza-Escobar |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (9 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: The COVID-19 pandemic had infected more than 3.5M people around the world and more than 250K people died in 187 countries by May 2020. The causal agent of this disease is a coronavirus whose onset of symptoms to death range from 6 to 41 days with a median of 14 days. This period is dependent on several factors such as the presence of comorbidities, age and the efficiency of the innate or adaptive immune responses. Methods: The effector mechanisms of both types of immune responses depend on the pathogen involved. In the case of a viral infection, the innate immune response may approach the harmful virus through pattern recognition receptors inducing an antiviral state. Results: On the other hand, the adaptive immune response activates antibody production to neutralize or eliminate the virus. Phenolics are plant secondary metabolites with many biological activities for plants and humans against infection. Chemical modification of proteins may enhance their biological properties; thus, a protein of medical interest, for instance, a viral protein can be used as a scaffold to build a biopharmaceutical conjugated or complexated with phenolics exhibiting structural complexity or biological activities to achieve effective phenolic-protein-based therapeutics like vaccine adjuvant complexes, immunogen conjugates, and antiviral conjugates. Conclusion: Pharmaceutical biotechnology applies the principles of biotechnology to develop biopharmaceuticals for protein-based therapeutics; such as adjuvants, recombinant proteins, monoclonal antibodies, and antivirals. As neither a vaccine nor a treatment for COVID-19 is currently available, this manuscript focuses on insights from pharmaceutical biotechnology into phenolic biopharmaceuticals against COVID-19 | ||
| 700 | 1 | |a Molina-Ramírez, Brenda |e verfasserin |4 aut | |
| 700 | 0 | |a María-de-la-Luz Sevilla-González |e verfasserin |4 aut | |
| 700 | 1 | |a Meza-Velázquez, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a García-Garza, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Velázquez Gauna, Sergio-Everardo |e verfasserin |4 aut | |
| 700 | 1 | |a Castillo-Maldonado, Irais |e verfasserin |4 aut | |
| 700 | 1 | |a Delgadillo-Guzmán, Dealmy |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera-Guillén, Mario-Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-Gallardo, Luis-Benjamín |e verfasserin |4 aut | |
| 700 | 0 | |a María-del-Carmen Vega-Menchaca |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Moreno, Agustina |e verfasserin |4 aut | |
| 700 | 1 | |a Pedroza-Escobar, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d Hilversum : Bentham Science Publ., 2000 |g 22(2021), 14, Seite 1848- |h Online-Ressource |w (DE-627)KFL00000636X |w (DE-600)2044611-1 |w (DE-576)273880926 |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:14 |g pages:1848- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-2010&volume=22&issue=14&spage=1848 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 14 |h 1848- | ||